GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman SyndromeGlobeNewsWire • 05/04/20
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/27/20
Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing TechnologyGlobeNewsWire • 04/01/20
REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic DisorderGlobeNewsWire • 03/31/20
GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman SyndromeGlobeNewsWire • 03/16/20
Ultragenyx (RARE) Down 31.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/14/20
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)GlobeNewsWire • 02/27/20
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/14/20
GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman SyndromeGlobeNewsWire • 01/15/20
Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue GuidanceGlobeNewsWire • 01/13/20
Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)GlobeNewsWire • 01/13/20
Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) DeficiencyGlobeNewsWire • 01/09/20
Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty PharmaGlobeNewsWire • 12/18/19
Ultragenyx (RARE) Up 13.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/19